InvestSMART

Island Pharmaceuticals Limited (ASX:ILA)

ALERT: Price-sensitive ASX Announcement for ILA
Current share price for ILA : $0.450 0.085 (23.29%)+
Announcement
Release
16 Jun 2026 9:58AM
Price at Release
$0.365
Full Release
download
Summary
Island Pharmaceuticals Limited, an Australian antiviral drug development company, presented at the Asia Dengue Summit in June 2026. The presentation highlighted the company's progress in developing ISLA-101, a drug aimed at preventing and treating mosquito-borne diseases like dengue fever. ISLA-101, originally developed as a cancer drug, has a well-established safety profile and has shown efficacy in both preclinical and clinical studies. The Phase 2a PROTECT study demonstrated positive top-line results, achieving desired plasma concentrations and reducing viremia and symptoms in the preventative cohort. The company is continuing to optimize its drug formulations and engage with strategic partners for further clinical trials. Island Pharmaceuticals is also developing Galidesivir, another antiviral with potential against various RNA viruses, including Zika and Ebola.
Key Points
  • Island Pharmaceuticals presented at the Asia Dengue Summit in 2026.
  • ISLA-101 is being developed to prevent and treat dengue fever.
  • The drug was originally developed as a cancer treatment.
  • Positive results were seen in the Phase 2a PROTECT study.
  • ISLA-101 reduced viremia and symptoms in trials.
  • The company is optimizing formulations and seeking clinical partners.
  • Island Pharmaceuticals is also working on Galidesivir for other viruses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.